Want to see AU:PYC full AI Analyst Report?
PYC Stock Chart & Stats
AU$1.28
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$1.28
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.83 - AU$1.71
Previous CloseN/A
Volume307.79K
Average Volume (3M)499.42K
Market Cap
AU$1.51B
Enterprise ValueAU$723.08M
Total Cash (Recent Filing)AU$120.69M
Total Debt (Recent Filing)AU$1.26M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Aug 27, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding983,510,440
10 Day Avg. Volume237,599
30 Day Avg. Volume499,416
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)3.84
Price to Sales (P/S)27.69
P/FCF Ratio-12.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.84Price Target Upside121.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)AU$5.00M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPYC-003 is now being assessed in a Phase I in healthy volunteers, entering a catalyst-rich period across all of its clinical programs.
Market ValidationNVS Acquisition of RGLS Further Validates MOA for Potentially Best-in-Class PYC-003.
ValuationThe upfront payment of US$7.00 per share infers an EV of US$0.8B – if applied to PYC’s capital structure, this generates a PYC valuation of AU$2.35 per share (US$1.50).
Bears Say
Competition And Market DynamicsAnalyst's recommendation is based on discounted, risk-adjusted multiples of 5 year forecast sales of the company’s three clinical candidates.
Probability Of SuccessApplying a 15% probability to the CVR, increases the valuation to AU$2.70 (US$1.72).
Speculative RiskBloom Burton is initiating research coverage of genetic medicine company, PYC Therapeutics, with a BUY rating (Speculative risk).
PYC Therapeutics Limited News
PYC FAQ
What was PYC Therapeutics Limited’s price range in the past 12 months?
PYC Therapeutics Limited lowest share price was AU$0.83 and its highest was AU$1.71 in the past 12 months.
What is PYC Therapeutics Limited’s market cap?
PYC Therapeutics Limited’s market cap is AU$1.51B.
When is PYC Therapeutics Limited’s upcoming earnings report date?
PYC Therapeutics Limited’s upcoming earnings report date is Aug 27, 2026 which is in 57 days.
How were PYC Therapeutics Limited’s earnings last quarter?
PYC Therapeutics Limited released its earnings results on Feb 23, 2026. The company reported -AU$0.039 earnings per share for the quarter, beating the consensus estimate of -AU$0.065 by AU$0.026.
Is PYC Therapeutics Limited overvalued?
According to Wall Street analysts PYC Therapeutics Limited’s price is currently Undervalued.
Does PYC Therapeutics Limited pay dividends?
PYC Therapeutics Limited does not currently pay dividends.
What is PYC Therapeutics Limited’s EPS estimate?
PYC Therapeutics Limited’s EPS estimate is -0.03.
How many shares outstanding does PYC Therapeutics Limited have?
PYC Therapeutics Limited has 983,510,440 shares outstanding.
What happened to PYC Therapeutics Limited’s price movement after its last earnings report?
PYC Therapeutics Limited reported an EPS of -AU$0.039 in its last earnings report, beating expectations of -AU$0.065. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PYC Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PYC Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$2.84 (121.87% Upside)
AU$2.84 (121.87% Upside)
Blogger Sentiment
Bullish
AU:PYC Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$99.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.71%
12-Months-Change
Fundamentals
Return on Equity
-30.03%
Trailing 12-Months
Asset Growth
133.24%
Trailing 12-Months
Company Description
PYC Therapeutics Limited
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
PYC Stock 12 Month Forecast
Average Price Target
AU$2.84
▲(121.87% Upside)
Technical Analysis
Opthea
―
Neuren Pharmaceuticals Limited
―
Starpharma Holdings Limited
―
Clarity Pharmaceuticals Ltd.
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---